Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905 Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Antineoplastic Combined Chemotherapy Protocols
  • Azacitidine
  • Leukemia, Myeloid, Acute
  • Leukemia, Myelomonocytic, Chronic
  • Myelodysplastic Syndromes

abstract

  • Addition of entinostat to AZA did not increase clinical response as defined by the protocol and was associated with pharmacodynamic antagonism. However, the prolonged administration of AZA by itself seems to increase HN rate compared with standard dosing and warrants additional investigation.

publication date

  • April 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3986386

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.50.3102

PubMed ID

  • 24663049

Additional Document Info

start page

  • 1242

end page

  • 8

volume

  • 32

number

  • 12